TD Cowen analyst Yaron Werber downgraded Alector (ALEC) to Hold from Buy without a price target The Phase 3 INFRONT-3 miss ends the company’s latozinemab program and the shares have few near-term catalysts, the analyst tells investors in a research note. The firm says that while Alector’s 49% headcount cut “is step in right direction,” its cash burn is high with runway to 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: